/images/ppid_59c68470-image-176302002882589234.webp)
/images/ppid_59c68470-image-176276509021853005.webp)
/images/ppid_59c68470-image-176276502940244741.webp)
/images/ppid_59c68470-image-176274259234846070.webp)
What is the story about?
Shares of Lincoln Pharmaceuticals Ltd. are trading lower on Thursday, November 13, after the company reported a decline in profit and operating performance for the September quarter.
The drugmaker's net profit fell 24% year-on-year to ₹20 crore, compared to ₹26 crore in the same period last year.
Revenue marginally rose by 1.4% to ₹163.4 crore from ₹161.2 crore in the base quarter.
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) declined 10.2% to ₹25.4 crore, while the EBITDA margin slipped to 15.5% from 17.6% last year.
Lincoln Pharma shares are now trading 2.05% lower at ₹518.95. The stock is down 40% so far in 2025.
The drugmaker's net profit fell 24% year-on-year to ₹20 crore, compared to ₹26 crore in the same period last year.
Revenue marginally rose by 1.4% to ₹163.4 crore from ₹161.2 crore in the base quarter.
EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) declined 10.2% to ₹25.4 crore, while the EBITDA margin slipped to 15.5% from 17.6% last year.
Lincoln Pharma shares are now trading 2.05% lower at ₹518.95. The stock is down 40% so far in 2025.
Do you find this article useful?
/images/ppid_59c68470-image-176292503019572759.webp)
/images/ppid_59c68470-image-176294254412368288.webp)
/images/ppid_59c68470-image-176285262199736883.webp)
/images/ppid_59c68470-image-17628625452727028.webp)
/images/ppid_59c68470-image-176291269507937110.webp)
/images/ppid_59c68470-image-176285503823426576.webp)
/images/ppid_59c68470-image-176294002846410077.webp)
/images/ppid_59c68470-image-176277753249825301.webp)